TY - JOUR
T1 - State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors
AU - Blackstock, Oni J.
AU - Wang, Karen H.
AU - Fiellin, David A.
N1 - Funding Information:
Funders: This work was funded by Robert Wood Johnson Foundation, Department of Veterans Affairs, National Institute of Mental Health, and Center for Interdisciplinary Research on AIDS. The funders had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.
PY - 2011/12
Y1 - 2011/12
N2 - BACKGROUND: In the United States, mortality from cardiovascular disease has become increasingly common among HIV-infected persons. One-third of HIV-infected persons in care may rely on state-run AIDS Drug Assistance Programs (ADAPs) for cardiovascular disease-related prescription drugs. There is no federal mandate regarding ADAP coverage for non-HIV medications. OBJECTIVE: To assess the consistency of ADAP coverage for type 2 diabetes, hypertension, hyperlipidemia, and smoking cessation using clinical guidelines as the standard of care. DESIGN: Cross-sectional survey of 53 state and territorial ADAP formularies. MAIN MEASURES: ADAPs covering all first-line drugs for a cardiovascular risk factor were categorized as "consistent" with guidelines, while ADAPs covering at least one first-line drug, but not all, for a cardiovascular risk factor, were categorized as "partially consistent". ADAPs without coverage were categorized as "no coverage". KEY RESULTS: Of 53 ADAPs, four (7.5%) provided coverage consistent with guidelines (coverage for all first-line drugs) for all four cardiovascular risk factors. Thirteen (24.5%) provided no coverage for all four risk factors. Thirty-six (68%) provided at least partially consistent coverage for at least one surveyed risk factor. State ADAPs provided coverage consistent with guidelines most frequently for type 2 diabetes (28%), followed by hypertension (25%), hyperlipidemia (15%) and smoking cessation (8%). Statins (66%) were most commonly covered and nicotine replacement therapies (9%) least often. Many ADAPs provided no first-line treatment coverage for hypertension (60%), type 2 diabetes (51%), smoking cessation (45%), and hyperlipidemia (32%). CONCLUSIONS: Consistency of ADAP coverage with guidelines for the surveyed cardiovascular risk factors varies widely. Given the increasing lifespan of HIV-infected persons and restricted ADAP budgets, we recommend ADAP coverage be consistent with guidelines for cardiovascular risk factors.
AB - BACKGROUND: In the United States, mortality from cardiovascular disease has become increasingly common among HIV-infected persons. One-third of HIV-infected persons in care may rely on state-run AIDS Drug Assistance Programs (ADAPs) for cardiovascular disease-related prescription drugs. There is no federal mandate regarding ADAP coverage for non-HIV medications. OBJECTIVE: To assess the consistency of ADAP coverage for type 2 diabetes, hypertension, hyperlipidemia, and smoking cessation using clinical guidelines as the standard of care. DESIGN: Cross-sectional survey of 53 state and territorial ADAP formularies. MAIN MEASURES: ADAPs covering all first-line drugs for a cardiovascular risk factor were categorized as "consistent" with guidelines, while ADAPs covering at least one first-line drug, but not all, for a cardiovascular risk factor, were categorized as "partially consistent". ADAPs without coverage were categorized as "no coverage". KEY RESULTS: Of 53 ADAPs, four (7.5%) provided coverage consistent with guidelines (coverage for all first-line drugs) for all four cardiovascular risk factors. Thirteen (24.5%) provided no coverage for all four risk factors. Thirty-six (68%) provided at least partially consistent coverage for at least one surveyed risk factor. State ADAPs provided coverage consistent with guidelines most frequently for type 2 diabetes (28%), followed by hypertension (25%), hyperlipidemia (15%) and smoking cessation (8%). Statins (66%) were most commonly covered and nicotine replacement therapies (9%) least often. Many ADAPs provided no first-line treatment coverage for hypertension (60%), type 2 diabetes (51%), smoking cessation (45%), and hyperlipidemia (32%). CONCLUSIONS: Consistency of ADAP coverage with guidelines for the surveyed cardiovascular risk factors varies widely. Given the increasing lifespan of HIV-infected persons and restricted ADAP budgets, we recommend ADAP coverage be consistent with guidelines for cardiovascular risk factors.
KW - AIDS
KW - AIDS drug assistance program
KW - HIV
KW - cardiovascular disease
KW - public assistance
UR - http://www.scopus.com/inward/record.url?scp=83655167317&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=83655167317&partnerID=8YFLogxK
U2 - 10.1007/s11606-011-1807-5
DO - 10.1007/s11606-011-1807-5
M3 - Review article
C2 - 21837376
AN - SCOPUS:83655167317
SN - 0884-8734
VL - 26
SP - 1426
EP - 1433
JO - Journal of General Internal Medicine
JF - Journal of General Internal Medicine
IS - 12
ER -
